saxagliptin + glyburide

Saxagliptin + glyburide is an **oral combination therapy** used for the treatment of type 2 diabetes mellitus. Saxagliptin is a **dipeptidyl peptidase-4 (DPP-4) inhibitor** that works by inhibiting the DPP-4 enzyme, leading to increased levels of active incretin hormones (GLP-1 and GIP), which enhance glucose-dependent insulin secretion and suppress glucagon secretion. Glyburide is a **sulfonylurea** that increases insulin release from pancreatic beta cells. The combination is used when glycemic control is inadequate with monotherapy, and has demonstrated greater reductions in HbA1c and fasting plasma glucose compared to uptitration of glyburide alone[1][2]. It is an adjunct to diet and exercise, typically reserved for patients not adequately controlled on glyburide alone.